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Abstract Intellectual disability (ID), also referred to as
mental retardation (MR), is frequently the result of genetic
mutation. Where ID is present together with additional
clinical symptoms or physical anomalies, there is often
sufficient information available for the diagnosing physi-
cian to identify a known syndrome, which may then educe
the identification of the causative defect. However, where
co-morbid features are absent, narrowing down a specific
gene can only be done by ‘brute force’ using the latest
molecular genetic techniques. Here we attempt to provide a
systematic review of genetic causes of cases of ID where no
other symptoms or co-morbid features are present, or non-
syndromic ID. We attempt to summarize commonalities
between the genes and the molecular pathways of their
encoded proteins. Since ID is a common feature of autism,
and conversely autistic features are frequently present in
individuals with ID, we also look at possible overlaps in
genetic etiology with non-syndromic ID.
Keywords Intellectual disability.Non-syndromic.Genetic
basis.Convergent pathways
Introduction
Definition and prevalence of intellectual disability
Intellectual disability (ID) is a common neurodevelopmen-
tal disorder that is characterized by an intelligence quotient
(IQ) of 70 or below, and deficits in at least two behaviors
related to adaptive functioning diagnosed by 18 years of
age (American Psychiatric Association 2000). The preva-
lence of ID is between 1% and 3% (Roeleveld et al. 1997;
Leonard and Wen 2002) and is present in every social class
and culture (Leonard and Wen 2002). Despite its universal
occurrence, there tends to be higher prevalence of ID in
areas of lower socioeconomic status and developing
countries, particularly for mild cases (Drews et al. 1995;
Roeleveld et al. 1997; Durkin et al. 1998; Durkin 2002;
Emerson 2007). It has been suggested that this discrepancy
is likely due to environmental factors (Roeleveld et al.
1997; Durkin et al. 1998; Emerson 2007).
Approximately 30% more males are diagnosed with ID
than females (American Psychiatric Association 2000;
McLaren and Bryson 1987). However, despite a higher ratio
of males to females among milder cases of ID, the ratio
decreases as IQ decreases (American Psychiatric Association
2000; McLaren and Bryson 1987). Some studies suggest that
severe ID may be more prevalent among females (Katusic et
al. 1996; Bradley et al. 2002), however these studies were
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Classification of ID by IQ and syndromic
vs. non-syndromic
ID is divided into 5 categories based on IQ: Mild,
moderate, severe, profound and unable to classify (DSM
IV). However, epidemiological studies often use a simpli-
fied classification, grouping their subjects into mild ID
(IQ50-70) and severe ID (IQ<50) (Ropers and Hamel
2005). While the prevalence of severe ID is relatively
stable, the prevalence of mild ID is variable and often
depends heavily on external environmental factors such as
level of maternal education, access to education/opportunity
and access to healthcare (Leonard and Wen 2002; Drews et
al. 1995; Roeleveld et al. 1997). Study design, age of
subjects, and the catchment population for the studies may
also contribute to the variability seen across mild ID
prevalence studies (Leonard and Wen 2002; Drews et al.
1995; Roeleveld et al. 1997).
In addition to categorization by severity/IQ level, ID can
also be grouped into syndromic intellectual disability (S-
ID) and non-syndromic intellectual disability (NS-ID). In S-
ID, patients present with one or multiple clinical features or
co-morbidities in addition to ID. While S-ID has a clear
definition, there is debate over the classification of NS-ID.
Traditionally, NS-ID has been defined by the presence of
intellectual disability as the sole clinical feature. However,
it has been a challenge to rule out the presence of more
subtle neurological anomalies and psychiatric disorders in
these patients, as they may be less apparent, or difficult to
diagnose due to the cognitive impairment. Additionally,
symptoms of some syndromes may be so subtle that they
are extremely difficult to diagnose unless the features are
looked for specifically in the context of a known genetic
defect previously associated with these features (Ropers
2006). Thus the distinction between S-ID and NS-ID is
often blurred.
Causes of ID
ID can be caused by environmental and/or genetic factors.
However, for up to 60% of cases, there is no identifiable
cause (Rauch et al. 2006). Environmental exposure to
certain teratogens, viruses or radiation can cause ID, as can
severe head trauma or injury causing lack of oxygen to the
brain. While these factors explain some cases of NS-ID, it
is also important to consider genetic etiology.
Genetic causes of ID are thought to be present in 25–50%
of cases, although this number increases proportionally with
severity (McLaren and Bryson 1987). Chromosomal abnor-
malities have been reported in ID, with a broad range of
prevalence, and many different types of aberrations have
been identified (Rauch et al. 2006). Autosomal trisomies
that are compatible with human viability and aneuploidies of
the X-chromosome almost always result in some degree of
ID as part of a syndrome, as illustrated by trisomy 21, or
Down Syndrome—the most common genetic form of ID
(Rauch et al. 2006). Additionally, pathogenic copy number
variants (CNV) have been found to be associated with ID in
a large number of studies, and will likely contribute to the
discovery of many ID causing genes in the future (Ropers
and Hamel 2005; Zahir and Friedman 2007).
Over the past 15 years many single gene causes of NS-
ID have been identified. Many of these NS-ID genes may
also cause S-ID, autism or other neurodevelopmental
phenotypes, making it likely that other genetic modifiers
or environmental factors may be involved in disease
etiology. It also stresses the importance of detailed
genotype/phenotype comparisons, which are often difficult
to elucidate. There is also a possibility that some instances
of NS-ID are multifactorial, with more than one gene
contributing to disease in an individual, however this has
not been well studied. Most known NS-ID genes are on the
X-chromosome, however the number of autosomal genes
associated with NS-ID is growing rapidly (Chelly et al.
2006).
Relevance of studying NS-ID genetics
Lionel Penrose was quoted as wishing to see each ID
individual “as an integral part of the human race in its
struggle for evolution and survival, unwittingly yielding
information of the greatest value in the progressive
understanding of the biological structure of the whole
group” (from Berg 1998). As Penrose implied, the
identification of the biological causes of NS-ID is necessary
to our understanding of human cognition and intellect.
Because NS-ID presents with intellectual impairment as the
only feature, genes that cause it are likely related to the
processes of learning and memory. These processes are
fundamental to our understanding of the formation of
normal intellectual capabilities, and in particular how
intellect develops from a neurological perspective. Addi-
tionally, finding genes that cause NS-ID might help us to
decipher relevant pathways that are involved in neuro-
logical development. Understanding these pathways may
aid us in treating or relieving symptoms of NS-ID in
certain cases. Knowledge of pathways involved in NS-ID
will also make it easier to select candidate genes to
analyze in research and clinically based studies. Under-
standing the genetics of a complex disease like NS-ID is
also relevant to genetic counseling in families with
affected individuals, particularly where consanguinity is
involved (Modell and Darr 2002).
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Homozygosity mapping
Given the innate heterogeneity of the NS-ID phenotypes, it
is of little surprise that its genetics are equally as complex.
It is thought that rare variants are likely responsible for
most cases of NS-ID, and this has been the focus of NS-ID
genetics for some time, although association studies are still
used to identify polymorphisms that potentially contribute
to the phenotype (e.g. SNAP25; Gosso et al. 2008). It is
likely that many rare variants across many genes result in
the same phenotype. Under the rare variants model of
causation, large consanguineous families are particularly
useful. Rare mutations, which may be identified in such
families, can provide us with information about the types of
etiological aberrations in NS-ID as well as the genes and
relevant pathways that may be essential for normal
neuronal functioning.
Our increasing ability to perform high throughput
analyses of genotype using microarrays has been a
significant contributor to the increased discovery rate of
NS-ID genes over the past 10 years (Lugtenberg et al.
2007). All of the genes identified for autosomal recessive
NS-ID thus far have been identified through microarray
technology combined with homozygosity mapping using
large consanguineous families. In these studies, large
multiplex families are obtained and detailed family histories
are taken. Affected family members are typically assessed
for additional clinical phenotypes that may suggest S-ID,
and are screened for more commonly known causes such as
fragile-X mutations and gross chromosomal anomalies.
DNA from the blood of affected family members, along
with one or two unaffected family members, is analyzed
using microarray technology and analysis software.
This method allows for a fast screen of individuals
genotypes, and allows the researcher to identify regions of
the genome that are homozygous for the same alleles
among all affected individuals. Typically (or at least
ideally), a single long stretch of DNA (often over 3 Mb),
is identified, and the disease causing mutation would lie
within this region. Use of consanguineous multiplex
families allows the identification of these linkage regions
with relative ease. The regions are then confirmed by
microsatellite analysis, and sequencing of genes within the
r e g i o nw i l lo f t e nl e a dt ot h ei d e n t i f i c a t i o no fad i s e a s e
gene.
Consanguinity is marriage between closely related
individuals, and is common in many countries around
the world, particularly in the Middle East and Asia. In
Pakistan—a country of 173 million people—consanguineous
unions make up 62.7% of marriages, and ~80% of which are
between first cousins, according to a national census (Hussain
and Bittles 1998). Other countries that also have high
prevalence of consanguinity include Iran, where the overall
prevalence is 40%, and India where prevalence ranges from
16% to 33% depending on the region (Hussain and Bittles
2000; Najmabadi et al. 2007).
Multiply affected consanguineous families have been
integral in determining autosomal recessive causes of
disease. The children of consanguineous individuals will
have more homozygous DNA than the offspring of an
outbred marriage. This leads to an increased likelihood of
rare, recessive disease-causing variants being inherited
from both parents. This is known as autozygosity or
homozygosity-by-descent (HBD), which occurs when a
rare allelic variant is passed down to offspring from a
common ancestor via both maternal and paternal lineages.
In populations where consanguinity is prevalent, there is a
significant increase in infant morbidity and mortality
(Modell and Darr 2002; Gustavson 2005; Khlat and Khoury
1991). One study showed that, in consanguineous popula-
tions, there were 10 times more recessively inherited
congenital conditions, many of which resulted in early
death (reported from the Birmingham Birth Study, as
reviewed in Modell and Darr 2002).
Advantages and disadvantages of homozygosity mapping
There are several reasons why homozygosity mapping has
been a successful approach for identifying rare genetic
variants. Intuitively, the co-segregation of large stretches of
homozygous alleles only in affected family members in a
consanguineous family increases the likelihood that the
region contains a gene that is relevant to the phenotype, and
statistics in the literature support this concept (Lander and
Botstein 1987). The method has been successfully utilized
to identify recessive causes of many diseases such as
Joubert syndrome, Charcot-Marie-Tooth syndrome, syn-
dromic deafness, and oligodontia (Noor et al. 2008; Bolino
et al. 2000; Senderek et al. 2003; Verpy et al. 2001; Noor et
al. 2009).
A major drawback is the scarcity of families in outbred
western populations that are suitable for this method. Also,
a lack of appropriate clinical assessment tools and infra-
structure may pose problems in some of the countries where
consanguineous families are more common. Aside from the
lack of large pedigrees, there are further obstacles in
identifying the gene of interest. Homozygosity mapping
studies, just like linkage studies, often identify very large
regions in which the disease gene may be found. Some of
these regions contain hundreds of genes, and selecting
relevant candidate genes can be problematic. Often, there is
no clear candidate gene, or there are many genes in the
region with no known function and thus selection of
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Sequencing (NGS) might be an effective way to overcome
this, however innate variation within the genome will likely
result in the identification of multiple genetic aberrations in
several genes that need to be ruled out as disease genes. For
instance, in one of the few reports so far on identification of
a recessive gene (DHODH, for Miller syndrome) through
exome sequencing, many variants were identified, however,
after filtering for known SNPs, just 9 candidate genes
remained (Ng et al. 2010). For application in consanguin-
eous families, this approach should be simpler, as one
would expect that the exome sequence data would also be
able to indicate regions of the genome containing large
stretches of homozygosity, so the candidate genes could be
narrowed down further to such a region.
Sequencing candidate genes
The sequencing of candidate genes has previously been
employed in the identification of many XLMR genes. The
X-chromosome has been a target in many studies looking
for causes of NS-ID because of the high male to female
ratio in the NS-ID population. The result is that most of the
known NS-ID genes are X-linked. Often, large cohorts of
individuals with ID are collected and target genes that have
a suspected role in development or brain function are
sequenced across the cohort. Recently, a re-sequencing of
the X-chromosome exome in a large cohort has led to the
identification of several novel NS-ID genes (Tarpey et al.
2009).
Typical genetic mapping strategies for autosomal domi-
nant disorders have been unsuccessful for NS-ID, due to
genetic heterogeneity and lack of suitable multiplex families,
as procreation of affected individuals is unlikely. Thus,
autosomal dominant NS-ID is likely to be sporadic, resulting
from de novo mutations. Sequencing candidate genes may be
the best approach for identifying autosomal dominant causes
of NS-ID. SYNGAP1, STXBP1,a n dSHANK3 were all
identified as autosomal dominant causes of NS-ID using
candidate gene sequencing (Hamdan et al. 2009a, b;
Michaud et al. 2009 Abstract).
While this approach can be effective, it may also require
much work, and will frequently be unsuccessful if the level
of genetic heterogeneity is as high as anticipated. However,
as our knowledge of biological pathways involved in ID
grows, our ability to select probable candidates will
increase, and this strategy may become more plausible.
Additionally, with improved technology such as NGS,
techniques, sequencing entire exomes for causes of ID will
become a less laborious and more productive screening
method. NGS is an emerging method that produces large
amounts of sequencing data quickly, at relatively low cost.
With this technology, it is possible to sequence through
large linkage regions, which can contain hundreds of genes,
with much less labor and in shorter time than traditional
sequencing. As well as application to critical linkage
regions, NGS can be applied to HBD regions, or whole
genome sequence analysis. It can also be applied in a more
directed (and thus more economical) approach, by whole
exome sequencing. This involves sequencing just the
coding portion of the genome—approximately 1% of our
genetic material. This method may be useful for identifying
genes when no linkage or susceptibility region is known, as
most disease causing mutations are likely to occur in exons.
Although NGS and exome sequencing present us with
many opportunities for high-throughput analysis of whole
genomes, some issues with the method have arisen. One
major concern is that there are likely to be many false
positives—there are thousands of common variants in the
human genome, many of which have not been well
documented. This is exemplified in the Tarpey et al.
(Tarpey et al. 2009) re-sequencing of the X-chromosome
exome. In this particular case, although standard rather than
next-generation sequencing was used, Tarpey et al. (Tarpey
et al. 2009) screened virtually the entire X-chromosome
exome in a large cohort for genes causing ID. It was found
that truncation of 1% or more of X-chromosome genes may
still be compatible with normal phenotype (Tarpey et al.
2009). There are many examples of nonsense mutations
that occur in the healthy population, where the resulting
haploinsufficiency is presumably compensated for by other
means (Tarpey et al. 2009). This demonstrates the need
for caution when interpreting results of large quantities
of sequencing data, such as that obtained by NGS and
exome sequencing studies. For instance, in the whole
genome sequencing of a patient with Charcot-Marie-Tooth
neuropathy, ~9,000 synonymous and ~9,000 non-
synonymous coding changes were identified, including
121 nonsense mutations (Lupski et al. 2010). (Also see
comment in previous section on identification of the
DHODH gene for Miller syndrome through exome
sequencing; Ng et al. 2010).
Characterization of chromosomal aberrations
Characterization of chromosomal aberrations by breakpoint
analysis has long been used as a method to identify
autosomal dominant disease causing genes. Determining
the exact location of the breakpoints and study of disrupted
genes has led to the discovery of several candidate genes
for non-syndromic autosomal dominant ID (NS-ADID).
DOCK8, MBD5, CDH15 and KIRREL3 were all identified
at chromosomal breakpoints of either gross chromosomal
abnormalities or CNVs (Griggs et al. 2008; Bhalla et al.
2008; Wagenstaller et al. 2007). For MBD5, CDH15 and
KIRREL3, further screening of these genes in cohorts of ID
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indicating the utility of this method in identifying disease
genes (Bhalla et al. 2008; Wagenstaller et al. 2007). X-
linked NS-ID genes have also been found using this
method. TSPAN7 was identified at the breakpoint of a
translocation in one individual, and then screening of an
NS-ID cohort led to the identification of mutations in
TSPAN7 in 2/33 families (Zemni et al. 2000).
Subtelomeric rearrangements and copy number variants
Copy number variants (CNV), which in the past few years
have been found to contribute significantly to common
genetic variation, also confer susceptibility to numerous
diseases. Although CNVs cover approximately 12% of the
entiregenomeinthe normalpopulation,rareCNVs havebeen
associated with various neuropsychiatric disorders such as
schizophrenia and autism (Redon et al. 2006;M a r s h a l le ta l .
2008; Stefansson et al. 2008), and have also been implicated
in ID (Zahir and Friedman 2007;K n i g h te ta l .1999)
Submicroscopic subtelomeric rearrangements have been
long implicated in the etiology of NS-ID. These rearrange-
ments include deletions as well as balanced translocations
and other chromosomal aberrations that are unable to be
seen under the microscope. Subtelomeric regions are
frequently a focus for analysis of chromosomal rearrange-
ments, as the density of genes in this region is greater than
in the rest of the genome (Saccone et al. 1992), and about
half of all segmental aneusomies involve subtelomeric and
terminal regions of chromosomes (Biesecker 2002). Sub-
telomeric rearrangements have been shown to be a
significant cause of ID in many chromosomal studies and
are thought to be responsible for 3–6% of cases (Knight et
al. 1999; Ledbetter and Martin 2007). In a 2002 meta-
analysis of studies of subtelomeric abnormalities in ID
cohorts, it was confirmed that this type of genetic aberration
is present in ~6% of cases, and that ~50% of them are
inherited (Biesecker 2002). These finding were quite
exciting because of the large number of cases with
subtelomeric abnormalities, and indicated that analysis of
subtelomeric regions could identify the molecular cause of
ID in many idiopathic individuals, as well as leading to
more effective clinical testing. With the advent of CGH
microarrays, identification of submicroscopic subtelomeric
rearrangements became more robust and more clinically
feasible (Stankiewicz and Beaudet 2007).
Currently, deletions in subtelomeric regions are also
picked up by CNV analysis—a type of analysis that has
become essential for determining the etiology of NS-ID.
With the increasing availability and sensitivity of micro-
array technology, pathogenic CNVs have been consistently
detected in 10–15% of individuals with ID across many
studies (Fan et al. 2007; Koolen et al. 2009; McMullan et
al. 2009) (as reviewed by Zahir and Friedman 2007). These
CNVs include both rare de novo, as well as rare inherited
mutations, which are still of unknown significance (but
may yet be important, since rare inherited subtelomeric
rearrangements have also been seen frequently; McMullan
et al. 2009).
As a demonstration of the successful application of
CNVs for identifying novel NS-ID genes, very recently,
SHANK2 was identified as an NS-ID and autism disease
gene, through the identification of CNVs that deleted
SHANK2 coding regions in two affected individuals.
Subsequent screening by sequencing in large cohorts
identified further NS-ID and autism patients with SHANK2
mutations (Berkel et al. 2010). Additionally, in the largest
study of its kind to date, SHANK2, SYNGAP1 and
ILRAPL1 CNVs were identified in autism probands,
illustrating the importance of CNV analysis and the
identification of genetic overlap between autism and NS-
ID (Pinto et al. 2010). CNV analysis will clearly play an
important role in the identification of further ID-related
genes. A great number of pathogenic CNVs have been
identified in NS-ID in recent years, and mapping these
breakpoints will likely be a successful method in determin-
ing autosomal dominant as well as X-linked causes of ID,
just as mapping breakpoints of cytogenetic abnormalities
has in the past (Ropers and Hamel 2005).
Non-syndromic X-linked intellectual disability
(or mental retardation; NS-XLMR)
The X-chromosome has historically been the most thorough-
ly studied chromosome with regard to NS-ID due to the high
male to female ratio. There are approximately 40 genes
known to cause NS-ID, and ~80% of these reside on the X-
chromosome. Some of these genes cause both S-ID and NS-
ID, depending on the mutation, or may even vary within
families, possibly modulated by additional factors. In the
case of ATRX (MIM: 300032) the same mutation in the same
family led to all family members having characteristic facial
features, except for one who had NS-ID (Guerrini et al.
2000). This gene has been shown to cause several other ID
syndromes, for which different mutations have been identi-
fied (Yntema et al. 2002; Gibbons et al. 2003;H o w a r de ta l .
2004).
Several other genes that classically cause syndromes
may also cause NS-XLMR. MECP2 (MIM: 300005), which
causes Rett syndrome, has been identified in a number of
NS-ID cases (Orrico et al. 2000; Couvert et al. 2001; Dotti
et al. 2002). Previously thought to be lethal in males, an
MECP2 missense mutation was found to cause severe
intellectual disability in males, and a much milder phenotype
in females (Dotti et al. 2002). These findings suggest that
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for certain mutations. Notably, in Rett syndrome, some
studies have demonstrated a genotype/phenotype correlation
in terms of severity, as well as for specific phenotypic
measures (Bebbington et al. 2008; Ham et al. 2005).
ARX (MIM: 300382) is one of the most frequently
mutated genes in XLMR. It encodes a transcription factor,
responsible for both gene repression and activation, that is
essential for normal development of the CNS. Mutations in
this gene are responsible for causing 7 distinct but over-
lapping ID-related phenotypes, including NS-ID (Friocourt
et al. 2006). One mutation in this gene, a 24bp in-frame
insertion leading to a lengthening of the polyalanine tract, is
found to be associated with at least four of these phenotypes
(Sherr 2003; Gecz et al. 2006). The reason for this striking
pleiotropy is currently unknown but could be essential for
understanding the role ARX in ID.
In all of these cases, where mutations of the same gene
cause a variable phenotype, it may be important to assess if
there are other factors are involved in phenotype expression.
Although the gene clearly causes the disease phenotype,
genetic background, epigenetic factors and other modifier
genes or environmental factors could alter how the phenotype
manifests. It might be useful to analyze these families’
genomes at much higher resolution in order to reveal other
genetic factors that contribute to the heterogeneous phenotype.
A number of X-linked genes cause NS-ID as the
predominant phenotype, and several of these are relatively
common in comparison to most NS-ID genes, which have
typically been identified in only one individual or family.
For instance, mutations in JARID1C (MIM: 314690) are
relatively common in NS-ID. It is likely involved in REST-
mediated transcriptional regulation and chromatin remodel-
ing (Tahiliani et al. 2007; Christensen et al. 2007). Other
X-linked genes that regulate gene expression such as
PQBP1 (MIM: 300463), MECP2, ATRX, and several zinc
finger genes are less common causes of XLMR (Ropers
2006; Gecz et al. 2009). SCL6A8 (MIM: 300036) is another
relatively common cause of XLMR (Salomons et al. 2001;
Hahn et al. 2002; Clark et al. 2006). It encodes a creatine
transporter, and mutations result in creatine deficiency
(Hahn et al. 2002). Creatine deficiency has been suggested
to be a relatively common cause of NS-ID (Lion-Francois et
al. 2006). Despite the biochemical effects of mutations in
SLC6A8, it is commonly accepted to be an NS-ID gene, as
the outward phenotypic manifestation of mutations is NS-ID.
As previously mentioned, the X-chromosome has been
highly scrutinized in the search for genes for NS-ID
(McLaren and Bryson 1987). However, reviews of X-
linked genes in ID have postulated that genes on the X-
chromosome likely account for only 10–12% of the genes
involved in genetic cases of ID (Ropers and Hamel 2005;
Mandel and Chelly 2004; Kleefstra and Hamel 2005).
Therefore genes on the X-chromosome appear to account
for some, but not all, of the increased male prevalence (the
X-chromosome contains ~4% of the genes in the genome).
It is probable that X-linked genes are not the sole reason for
gender differences, and that other factors, both genetic and
non-genetic, might influence the sex ratio. These could
include environmental influences or increased penetrance of
certain autosomal mutations in males.
Non-syndromic autosomal dominant intellectual
disability (NS-ADID)
Autosomal inheritance is a plausible mechanism for many
NS-ID cases, and in recent years it has become the subject
of intensive study. In contrast to XLMR genes, which
contain both missense and nonsense mutations relatively
frequently, the NS autosomal dominant and recessive genes
identified so far appear to have mostly truncating mutations
(see Table 1). For reasons discussed previously, only a few
genes have been found that cause NS-ADID. MIM uses the
acronym MRD for loci for “mental retardation, autosomal
dominant”. For MRD1 (MIM 156200), the methyl binding
domain 5 gene, MBD5 (MIM 611472) on 2q23.1 was
identified by SNP microarray analysis, indicating a 200Kb
de novo deletion, removing at least 6 exons of the gene in a
female proband with sandal-toe and epilepsy but no facial
dysmorphic features (Wagenstaller et al. 2007). An addi-
tional 4 S-ID probands with MBD5 missense mutations
were also identified in this study.
The gene for MRD2, on 9p24, dedicator of cytokinesis
8( DOCK8; MIM 611432) was identified in 2 unrelated
patients, by mapping breakpoints of a deletion and
translocation respectively (Griggs et al. 2008).
Combining the mapping of translocations and CNV
breakpoints with candidate gene sequencing has been an
important method for identifying ADID genes. The MRD3
and MRD4 genes, CDH15 (MIM: 114019) and KIRREL3
(MIM: 607761) respectively, both were mapped to the
chromosomal breakpoint of an individual with a balanced
t(11;16)(q24.2;q24) translocation presenting with severe ID
and several other dysmorphisms (Bhalla et al. 2008). The
two genes, both encoding putative cell-adhesion proteins,
were then sequenced in 600 ID patients, and several
missense mutations not found in the general population
were identified—4i nCDH15 and 3 in KIRREL3 (Bhalla et
al. 2008). Some of the patients had additional clinical
features, while others were NS-ID cases. This confirms the
utility of chromosomal breakpoints for identifying candi-
date genes for ADID. It is also possible that additive effects
of mutations in more than one ID gene may be involved in
some instances, however evidence to support this is
lacking, and additive gene effects are poorly understood.
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cause disease and mode of inheritance
Gene Name OMIM
Ref
X-linked/Autosomal
(MR/ID)
Cytogenetic
Band
a
Phenotypic
Expression*
Mutation Type Reference
ACSL4 300157 X-linked
(MRX63 & 68)
Xq22.3 Males: MR Missense, splice site (Meloni et al. 2002)
Females: Variable
AFF2/
FMR2
300806 X-linked Xq28 Dominant
b 5′ GGC repeat
amplification leading
to methylation
(Gecz et al. 1996)
AGTR2 300034 X-linked
(MRX88)
Xq23 Recessive Missense, Truncating (Vervoort et al. 2002)
AP1S2 300629 X-linked
(MRX59)
Xp22.2 Recessive Truncating (Tarpey et al. 2006)
ARHGEF6 300267 X-linked
(MRX46)
Xq26.3 Recessive Splice site (Kutsche et al. 2000)
ARX 300382 X-linked Xp21.3 Males: MR;
Females: Low-
normal IQ
In frame insertions/
deletions, missense
(Bienvenu et al. 2002;
Stromme et al. 2002a, b;
Troester et al. 2007)
ATRX 300032 X-linked Xq21.1 Recessive Missense (Yntema et al. 2002)
BRWD3 300553 X-linked
(MRX93)
Xq21.1 Recessive Missense, frame-shift (Field et al. 2007)
CASK 300172 X-linked Xp11.4 Recessive Missense (Tarpey et al. 2009;
Hackett et al. 2009)
CC2D1A 610055 Autosomal
(MRT3)
19p13.12 Recessive Truncating (Basel-Vanagaite
et al. 2006)
CDH15 114019 Autosomal
(MRD3)
16q24.3 Dominant Missense (Bhalla et al. 2008)
CRBN 609262 Autosomal
(MRT2)
3p26.3 Recessive Truncating (Higgins et al. 2004)
DLG3 300189 X-linked
(MRX90)
Xq13.1 Males: MR Truncating (Tarpey et al. 2004)
Females: Variable
DOCK8 611432 Autosomal
(MRD2)
9p24.3 Dominant Deletion, translocation (Griggs et al. 2008)
FGD1 305400 X-linked Xp11.22 Recessive Missense (Lebel et al. 2002)
FTSJ1 300499 X-linked
(MRX9 & 44)
Xp11.23 Recessive Truncating, missense (Freude et al. 2004)
GDI1 300104 X-linked
(MRX41 & 48)
Xq28 Dominant
b Truncating, missense (D’Adamo et al. 1998;
(Bienvenu et al. 1998)
GRIK2 138244 Autosomal
(MRT6)
6q21 Recessive Truncating (Motazacker et al. 2007)
HUWE1 300697 X-linked
(MRXS-Turner
& MRX17)
Xp11.22 Recessive Missense,
microduplication
(Froyen et al. 2008)
IL1RAPL1 300206 X-linked
(MRX21)
Xp21.3–
p21.2
Recessive Truncating, deletion (Carrie et al. 1999;
Nawara et al. 2008)
JARID1C
(KDM5C)
314690 X-linked Xp11.22 Recessive Truncating, missense (Jensen et al. 2005)
KIRREL3 607761 Autosomal
(MRD4)
11q24.2 Dominant Missense (Bhalla et al. 2008)
MAGT1 300715 X-linked
(MRX95)
Xq21.1 Dominant Missense (Molinari et al. 2008)
MBD5 611472 Autosomal
(MRD1)
2q23.1 Dominant Deletion, missense (Wagenstaller et al. 2007)
MECP2 300005 X-linked
(MRXS13)
Xq28 Dominant Truncating, missense,
deletion
(Orrico et al. 2000)
NLGN4 300427 X-linked
(AUTSX2)
Xp22.31–
p22.32
Recessive Truncating (Laumonnier et al. 2004)
OPHN1 300127 X-linked Xq12 Recessive Truncating, deletion (Billuart et al. 1998;
Philip et al. 2003)
PAK3 300142 X-linked
(MRX30)
Xq22.3 Recessive Truncating, missense,
splice site
(Allen et al. 1998;
Rejab et al. 2008)
188 J Neurodevelop Disord (2010) 2:182–209CDH15 is a cadherin gene that is involved in intercellular
adhesion and is strongly expressed in cerebellum (Bhalla et
al. 2008). KIRREL3 encodes a protein of unknown
function, although it has been shown to co-localize and
interact with CASK, an NS-ID-associated synaptic protein,
and is expressed in adult and fetal brain (Bhalla et al. 2008).
It also shares structural aspects with IL1RAPL1, one of the
well-established X-linked NS-ID genes. Both contain
several IG-like domains, an IGC2 domain, and a trans-
membrane region.
SYNGAP1 (MIM: 603384; MRD5), encoding SynGAP, a
component of the NMDA-receptor (NMDAR) complex,
was initially screened because mouse models carrying
heterozygous mutations in Syngap were observed to have
impaired learning and synaptic plasticity, along with defects
in LTP (Hamdan et al. 2009a, b;K i me ta l .2003;
Komiyama et al. 2002). The homozygous mutation in
Syngap is post-natally lethal, suggesting that SYNGAP1
may be a plausible candidate for ADID in humans (Kim et
al. 2003). Sequencing of the gene in a cohort of NS-ID
probands led to the discovery of 3 unrelated individuals
with heterozygous mutations in SYNGAP1 (Hamdan et al.
2009a, b). Two were nonsense and one was a frame shift
leading to truncation (Hamdan et al. 2009a, b). NMDARs
play a role in glutamate-activated excitation of postsynaptic
neurons, and have been implicated in memory formation
and synaptic plasticity. This gene has also been implicated
in autism in a large-scale CNV analysis in which one
proband was found to have a CNV loss overlapping the
entire gene (Pinto et al. 2010).
Additionally, mutations in SHANK2 (MIM: 603290)
have been reported in cases of autism and NS-ID. Four
Table 1 (continued)
Gene Name OMIM
Ref
X-linked/Autosomal
(MR/ID)
Cytogenetic
Band
a
Phenotypic
Expression*
Mutation Type Reference
PQBP1 300463 X-linked Xp11.23 Recessive Missense (Kalscheuer et al. 2003)
PRSS12 606709 Autosomal
(MRT1)
4q26 Recessive Truncating (Molinari et al. 2002)
PTCHD1 X-linked Recessive Deletion (Noor et al. in press)
RPS6KA3 300075 X-linked
(MRX19)
Xp22.12 Recessive Missense (Merienne et al. 1999)
SHANK2 603290 Autosomal 11q13.3–
13.4
Dominant CNV deletion, missense (Berkel et al. 2010)
SHROOM4 300579 X-linked Xp11.22 Dominant Translocation; missense (Stocco dos Santos et al.
2003; Hagens et al.
2006)
SLC6A8 300036 X-linked Xq28 Dominant
b Truncating, missense (Salomons et al. 2001;
Hahn et al. 2002)
STXBP1 602926 Autosomal 9q34.11 Dominant Deletion, nonsense (Hamdan et al. 2009a, b)
SYNGAP1 603384 Autosomal
(MRD5)
6p21.32 Dominant Truncating (Hamdan et al. 2009a, b)
SYP 313475 X-linked Xp11.23 Recessive Truncating, missense (Tarpey et al. 2009)
TSPAN7 300096 X-linked
(MRX58)
Xp11.4 Recessive Truncating, missense (Zemni et al. 2000)
TRAPPC9 611966 Autosomal
(MRT13)
8q24.3 Recessive Truncating (Mir et al. 2009
TUSC3 601385 Autosomal
(MRT7)
8p22 Recessive Truncating (Garshasbi et al. 2008;
Molinari et al. 2008)
UPF3B 300298 X-linked
(MRXS14)
Xq24 Recessive Truncating (Tarpey et al. 2007)
ZNF41 314995 X-linked
(MRX89)
Xp11.3 Variable Missense, splice site (Shoichet et al. 2003)
ZNF674 300573 X-linked
(MRX92)
Xp11.3 Recessive Truncating (Lugtenberg et al. 2006
ZNF711 314990 X-linked Xq21.1 Recessive Truncating (Tarpey et al. 2009)
ZNF81 314998 X-linked
(MRX45)
Xp11.23 Recessive Missense (Kleefstra et al. 2004)
*In X-linked genes, male and female values reflect the effects of one variant
aCytoband reported in UCSC Genome Browser
bless severe in females
J Neurodevelop Disord (2010) 2:182–209 189unrelated individuals with NS-ID and 7 unrelated individ-
uals with autism have either CNV deletions or sequence
mutations in SHANK2 (Berkel et al. 2010). One of the NS-
ID patients had a de novo CNV deletion overlapping exon 7
of the gene, and the other three all have inherited missense
mutations, one of which is also found in an unrelated
autism proband (Berkel et al. 2010). Two of the individuals
presenting with NS-ID in this study also show autistic
features, but do not meet the autism diagnosis criteria.
Mutations in SHANK2 on 11q13 were identified by CNV
analysis with subsequent gene sequencing in a large autism
and NS-ID cohort (Berkel et al. 2010). SHANK proteins
are scaffolding proteins that are highly abundant at the post-
synaptic density. Recent work has shown that HOMER and
SHANK form a mesh-like matrix that creates a framework
for structure and protein assembly at the post-synaptic
density, and may be important for synaptic plasticity
(Hayashi et al. 2009).
Non-syndromic autosomal recessive intellectual
disability (NS-ARID)
MIM uses the acronym MRT for “mental retardation,
autosomal recessive”. To date, only 6 MRT genes have
been published. Only two of the NS-ARID genes published
to date have been identified in more than one family. The
first of these to be identified was TUSC3 (MIM: 601385),
for MRT7, which encodes a protein that is likely involved in
catalyzing the transfer of a 14-sugar oligosaccharide from
dolichol to nascent protein, an essential step in N-linked
protein glycosylation (Molinari et al. 2008; Garshasbi et al.
2008). A recent study has also demonstrated that TUSC3 is
necessary for Mg
2+ regulation, and knockdown of this gene
causes decreased total and free intracellular Mg
2+ in human
cell lines, as well as arrested or abnormal development in
zebrafish embryos (Zhou and Clapham 2009).
The second NS-ARID gene to be identified in more than
one family is TRAPPC9 (MIM: 611966), for MRT13,
which encodes a protein called NIBP. TRAPPC9 mutations
have been found in 4 unrelated families from different parts
of the world (Mir et al. 2009; Philippe et al. 2009; Mochida
et al. 2009). NIBP directly interacts with NIK and IKKβ,
which results in the activation the NF-κB pathway (Hu et
al. 2005). It has been shown to be involved in axonal
outgrowth in vitro, and may be involved in neuronal cell
survival (Hu et al. 2005). Interestingly, the same truncating
allelic variant segregates in two families from two different
countries (Mir et al. 2009; Mochida et al. 2009). It is
possible that this represents a historic variant passed down
through many generations, and may represent a relatively
common cause of NS-ARID, although this requires further
investigation. It is also possible that the two families are
distantly related although this is thought unlikely due to the
distance between Pakistan and Israel, and the limited
transmigration of the populations involved.
All other published NS-ARID genes have been identified
in only one family. PRSS12 (MIM: 606709), also known as
neurotrypsin, was the first of such genes to be identified
(Molinari et al. 2002). It encodes a trypsin-like serine
protease, which is expressed in the embryo, and is likely
involved in synapse maturation and neural plasticity
(Molinari et al. 2002; Gschwend et al. 1997; Wolfer et al.
2001). It functions in the proteolytic cleavage of agrin at the
synapse, which requires postsynaptic NMDAR activation
(Matsumoto-Miyai et al. 2009; Stephan et al. 2008; Reif et
al. 2007). The result of mutation in these individuals is
moderate to severe intellectual disability (Molinari et al.
2002).
CRBN (MIM: 609262) encodes the ATP-dependant Lon
protease cereblon that is directly involved in assembly and
surface expression of large-conductance Ca
2+-activated K
+
channels, which function in the control of neuronal
excitability and transmitter release (Higgins et al. 2004;J o
et al. 2005). Mutations in CRBN appear to disturb the
development of large-conductance Ca
2+-activated K
+ chan-
nels, which causes increased intracellular Ca
2+ sensitivity
and results in faster activation, and slower deactivation
kinetics (Higgins et al. 2008). Nonsense mutations in this
gene result in mild ID.
CC2D1A (MIM: 610055) codes for a protein that is a
calcium-regulated transcriptional repressor and is a putative
candidate for regulation of the NF-κB pathway (Basel-
Vanagaite et al. 2006; Matsuda et al. 2003). CC2D1A, also
known as Freud-1 (five prime repressor under dual
repression binding protein-1), is also believed to regulate
transcriptional repression of the serotonin 1A receptor gene
HTR1A, and the dopamine receptor DRD2 gene (Ou et al.
2003; Rogaeva et al. 2007).
Nonsense mutations in GRIK2 (MIM: 138244) also
cause NS-ARID (Motazacker et al. 2007). GRIK2 encodes
a protein called GLuR6, which is a subunit of a kainate
receptor (KAR). KARs are ionotropic glutamate receptors
which respond to the excitatory neurotransmitter l-
glutamate, similar to NMDA or AMPA receptors. They
are highly expressed in the brain, particularly in the
hippocampal mossy fibers, where GLuR6 has been found
to modulate long-term potentiation (LTP) in mouse models
(Bortolotto et al. 1999; Contractor et al. 2001). GLuR6
knockout mice show decreased LTP in mossy fibers; a
phenotype which could be rescued by application of low
levels of K
+ indicating that KARs induce LTP via
depolarization of the pre-synaptic terminal (Contractor et
al. 2001; Schmitz et al. 2003). LTP in the hippocampus has
been implicated as a mechanism for memory formation and
learning (Bliss and Collingridge 1993; Fedulov et al. 2007).
190 J Neurodevelop Disord (2010) 2:182–209Although there are only 6 known genes that segregate
with NS-ARID, a further 8 loci have been identified
through HBD mapping which are likely to lead to more
gene discoveries in the near future (Najmabadi et al. 2007;
Garshasbi et al. 2009 Abstract; Uyguner et al. 2007; Rafiq
et al. 2010).
Three additional genes have been suggested as NS-
ARID genes and reported at recent genetics meetings, but
have yet to be published. Two of these genes were found to
have missense mutations, which would represent the first
instances of missense mutations causing autosomal NS-ID
(Najmabadi et al. 2009 Abstract; Moheb et al. 2009
Abstract). One of these is the ZNF526 gene, which encodes
a C2H2 zinc finger protein that is expressed in the brain
(Moheb et al. 2009 Abstract). This mutation has been
identified in two Iranian families. The other gene with
missense mutations is ST3GAL3 (MIM: 606494), which
codes for a glycosyl tranferase that catalyzes the transfer of
sialic acid to galactose-containing substrates, and has been
identified in two Iranian families (Najmabadi et al. 2009
Abstract; Grahn et al. 2002). Two more unrelated families
have been mapped to the same locus, 1p34 (Najmabadi et al.
2009 Abstract). Finally, two unrelated families were found
to have nonsense and frame shift mutations in ZC3H14,
which is a recently described CCCH-type zinc finger gene
(Garshasbi et al. 2009 Abstract; Leung et al. 2009). These
three genes, if validated, will be interesting because all of
them have been identified in more than one family.
See Table 1 for a summary of NS-ID genes.
Synthesizing our knowledge: the search for common
pathways
As our knowledge of genes involved in ID expands and the
number of genes we identify increases, common pathways
are emerging. If a number of common pathways for ID can
be confirmed, then, even without knowing which gene is
involved in an individuals ID, we may be able to develop
tests for specific biochemical markers that can indicate
whether the level of activity of certain pathways is
deficient. It is already well established that synaptic
proteins are involved in memory and learning, and have
been implicated in ID. See Table 2 for a summary of
functions and domains of known NS-ID genes, and Table 3
for a summary of known protein interactions.
Ionotropic glutamate receptors and excitatory synapses
Ionotropic glutamate receptors have long been suspected to
be involved in the etiology of neuropsychiatric disease.
Several examples of mutations in glutamate activated
receptors and their downstream effectors are present in
NS-ID (see Fig. 1). The MRT6 gene GRIK2 encodes
GLuR6, which is a subunit of a Kainate receptor (KAR).
Likewise, the MRD5 gene SYNGAP1 encodes SynGAP—a
GTPase activating protein that is part of the NMDA
receptor (NMDAR) complex, binding to the NR2B subunit
(Kim et al. 2005). The NMDAR is a well-characterized
ionotropic glutamate receptor. SynGAP is a negative
regulator of NMDAR mediated ERK activation and causes
inhibition of the Ras/ERK pathway (Kim et al. 2005).
Over-expression of SynGAP has also been shown to down
regulate GLuR1, a subunit of AMPA receptors (AMPAR), a
class of ionotropic glutamate receptors which are regulated
by the Ras/ERK pathway (Kim et al. 2005; Rumbaugh et
al. 2006). Likewise, Syngap knockout mice implicate
SynGAP in the regulation of LTP and AMPAR expression
(Komiyama et al. 2002).
SAP102 (MRX90), which is part of the membrane-
associated guanylate kinase (MAGUK) protein family and
the product of DLG3, is also part of the NMDAR complex
(Tarpey et al. 2004). MAGUKs are scaffolding proteins
involved in the clustering, targeting and anchoring of
ionotropic glutamate receptors in the excitatory postsyn-
aptic density (Gardoni 2008). SAP102 directly interacts
with the NR2B and NR2A subunits of the NMDAR and is
likely to have a role in the clustering and targeting of these
receptors (Muller et al. 1996). The protein is expressed at
excitatory synapses, particularly during early brain devel-
opment (Sans et al. 2000). When knocked down, SAP102
has been found to decrease AMPAR and NMDAR
excitatory postsynaptic currents (EPSC), while over ex-
pression increases EPSC (Elias et al. 2008). Another
MAGUK family protein gene, CASK, is frequently mutated
in NS-ID as well (Tarpey et al. 2009; Hackett et al. 2009).
It is a synaptic scaffolding protein, and acts as an
Mg
2+-independent neurexin kinase, and interacts with
many other families of proteins at cellular junctions (Hata
et al. 1996; Mukherjee et al. 2008). It also directly interacts
with GLuR6 (Coussen et al. 2002).
Mutations in IL1RAPL1, a gene with several known
mutations in NS-ID and autism, result in the incorrect
localization of the MAGUK family protein PSD-95 (DLG4),
which is important for organization and function of NMDA
receptors, ion channels and other signaling proteins (Carrie
et al. 1999; Gardoni 2008; Kim and Sheng 2004; Pavlowsky
et al. 2010). IL1RAPL1 has been shown to interact with
PSD-95, and knockout of this gene decreased the post-
synaptic density (PSD) and the localization of PSD-95 at
excitatory synapses. Loss of IL1RAPL1 also results in a
decrease of activity in the JNK pathway, which led to
decreased phosphorylation of PSD-95 (Pavlowsky et al.
2010). It has also been shown to be important for the
formation of excitatory synapses in vivo (Pavlowsky et al.
2010). PSD-95 directly interacts with several known NS-ID
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J Neurodevelop Disord (2010) 2:182–209 193associated proteins including: CASK, SynGAP, GLuR6 and
neuroligins (Kim and Sheng 2004).
Three other synaptic proteins, NLGN4, SHANK2 and
SHANK3, have also been identified as causes of NS-ID and/
or autism. NLGN4 is a protein that acts in neuronal cell
adhesion. It is an important element in postsynaptic differen-
tiation, forming complexes with β-neurexins and PSD-95
(Ichtchenko et al. 1995; Irie et al. 1997; Scheiffele et al.
2000). NLGN4 is linked to glutamatergic postsynaptic
proteins and neuroligin/neurexin complexes appear to be
sufficient for synaptogenesis (Graf et al. 2009). Interestingly,
heterozygous translocations and CNVs disrupting neurexin 1
(NRXN1), which interacts with NLGN4 at the synapse, have
been associated with autism (Kim et al. 2008; Autism
Genome Project Consortium et al. 2007), and homozygous
mutation of NRXN1 causes the S-ID disorder Pitt-Hopkins-
like syndrome-2 (PTHSL2; Zweier et al. 2009). NRXN1 also
interacts with the NS-ID causing scaffolding protein CASK,
as discussed earlier in this review (Hata et al. 1996). SHANK2
and SHANK3 encode scaffolding proteins present at the post-
synaptic density and in dendrites. They are important for
scaffolding in the post-synaptic density—connecting ion
channels, neurotransmitter receptors and other membrane
proteins to the actin cytoskeleton—and act as a structural
framework at this site (Boeckers et al. 2002; Hayashi et al.
2009). They are also likely to play a role in neuronal
plasticity (Boeckers et al. 2002; Hayashi et al. 2009).
OPHN1 encodes an activity-dependant protein that
interacts with AMPARs and is essential for their stabiliza-
tion, thus playing a significant role in synaptic maturation
and plasticity (Nadif Kasri et al. 2009). Interestingly,
GRIA3, which causes S-ID is a subunit of AMPAR. The
S-ID phenotype caused by GRIA3 is variable, but one case
presented with only ID and aesthenic body habitus (Wu et
al. 2007; Bonnet et al. 2009). Due to the small number of
mutations found in this gene, it is difficult to discern if the
ID in certain individuals is actually syndromic. The finding
that ID can be caused by mutations in all three classes of
ionotropic glutamate receptors suggests that the activity and
regulation of glutamatergic synapses is essential for normal
cognition. This is not surprising, as LTP and LTD often
originate from these synapses, and are processes that are
thought to be important for synaptic plasticity, memory and
learning (Malenka and Bear 2004).
Other synaptic and neuronal proteins in NS-ID
Activity downstream of ionotropic glutamate receptors is
also important in understanding the etiology of NS-ID.
PRSS12 encodes the protein neurotrypsin, a synaptic
protease that is activated by the NMDA receptor (Molinari
et al. 2002; Matsumoto-Miyai et al. 2009). It acts in the
synapse to cleave agrin, which is present at neuromuscular
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194 J Neurodevelop Disord (2010) 2:182–209Table 3 NS-ID Gene Interactions Interactions were determined
using 4 databases: BioGRID (www.thebiogrid.org), HPRD (www.
hprd.org), String (www.string-db.org) and IntAct (http://www.ebi.ac.
uk/intact). Interactions from all 4 databases are recorded for each
gene. For each interaction identified on these websites there is a link
to the appropriate publication for that interaction. In BioGRID, the
publication can be found by clicking on the “publication” link. For
HPRD the publication can be found by clicking on the “experiment
type” next to each interaction. For String, clicking on the “experi-
ments” link and then on the “details” for the interaction brings up the
published abstract. For IntAct, the EBI identification number has been
provided for each protein, and this can be queried on the IntAct
database to find the publication information. Interactants not found in
these databases have been cited independently. *Interactions have
been identified in animal studies
Gene Name Interacting proteins (IntAct; STRING; BioGRID; HPRD)
ACSL4 SPG20 (EBI-2643801)
AFF2/FMR2 GRB2 (EBI-1964238); NCK1 (EBI-1968993); PLCG1 (EBI-1971165); MAPK14 (EBI-1959498)
AGTR2 AGT; AGTRAP; ACE; MTUS1; TIMP3 (EBI-1749967); GNAI2*; GNAI3*; ZBTB16; PIK3CB; ERBB3
AP1S2 AP1G2 (EBI-516314); AP1G1 (EBI-516318); AP1S1 (EBI-1073310); GGA3
ARHGEF6 GIT1; PKLR; BMPR1B; PAK1-3; ARHGEF7; SMAD1-3; TGFBR1; TGFBR2; PARVB; CAPNS1; CDC42; EPHB2;
YWHAG; SH2D1A; ADAM15;
ARX None known
ATRX DAXX (EBI-371424); NEK1 (EBI-695931); PTN (EBI-731356); HDAC1; HDAC4; RAD51; ATN1; FAM190B (EBI-731347);
EZH2; EIF4A2 (EBI-1069160); MECP2*; SMC1A; CBX5; PTPN4; H3F3A; H3F3B; KIAA1377; LUC7L2; KIAA1128
BRWD3 UBXD7 (EBI-2009865)
CASK LIN7A; DLG1; TBR1 (EBI-1216781); KCNJ12 (EBI-704591); APBA1; PARK2; RPH3A (EBI-1216824); F11R; ATP2B4;
SDC1-4; DLG4; TSPYL2; ID1 (EBI-1215556); KNCJ4 (EBI-706129); NPHS1; CNTNAP2; CNTNAP4; HGS; SPATA2;
UIMC1 (EBI-2515432); LIN7C; EPB41 (EBI-1219323); C16ORF70; CD2AP; FCHSD2 (EBI-1215794); LIN7B; EPS8;
GRIK2; RAB3A; CASK; KCNJ2 (EBI-706107); DLG1; CADM1; NRXN1-3; DFNB31; CASKIN1; TANC1; GRIN2A;
KCNA4; GLS2; NF1; HTR2C; ARHGEF7; KIRREL3 (Bhalla et al. 2008)
CC2D1A CHMP4A; CHMP4C
CDH15 CTNNA1; CTNNB1; JUP; GNA12; BOC; ARVCF; CDON; CDH9; CDH7
CRBN DDB1* (EBI-2559059); CSN6 (EBI-2510262); CUL4A
DLG3 GRIN2A; GRIN2B; EXOC4; KNCJ12 (EBI-704591); APC; PTK2B; DLG4; SYNGAP1; GDA; CRIPT; GRIN2C; SSCR2*;
GUCY1A2; NLGN2; ATP2B4; NLGN1; GRIK2, DLGAP1; NLGN3; ATP2B2; GRIK5; SEMA4C; EXOC7; KRT85 (EBI-
1085330); KRT34 (EBI-1077921); KRT35; KRT31 (EBI-1082542); ERBB4 (EBI-80454); CAMK2A (EBI-1068669);
CUL2 (EBI-1081586); ANXA1 (EBI-1077519); S100A3 (EBI-1081429); EXOC3; HIST1H2BC; KLHDC3 (EBI-1081381);
KRT82 (EBI-1084718); LRP2; CALM1; CNKSR2; KIF1B; MAPK12; KCNA4; SCN4A; ABCA1 (EBI-784253); LPHN1;
DLG1; LIN7A; GRIN1; DLGAP4; CACNG2; SCN5A; GLS2; KCNJ2; DLGAP3; GRIK5; PAEP; SCN4A; IDUA (EBI-
737171); INSM1 (EBI-737174); MORN2 (EBI-737180); PPP1R14A* (EBI-776423); DLGAP2* (EBI-389360); MDH1 (EBI-
735148); SF3B3 (EBI-737189); LRFN2* (EBI-877173); PLK2 (EBI-735154); RBP5 (EBI-737168); TRIM41 (EBI-737192);
HAP1 (EBI-732554); SCN2A (EBI-737186); RAB31 (EBI-737183); MCM2 (EBI-732557); B3GNT8 (EBI-737165);
DOCK8 CDC42; RAC1; RHOJ; RHOQ
FGD1 CDC42; ELMO1; ABP1; CTTN; RHOA; RHOG; RHOU; RHOC; RAC2; IFNB1
FTSJ1 DMWD; FBL; NOP58;
GDI1 RAB1B; RAB6A; RAB3B; RAB9A; RAB27A; PSEN1; RHOH; CDC42; RAC2; RHOA; RABAC1; EPB41; SPOP
GRIK2 DLG4; SDCBP; PICK1; DLG1; GRIK5; GRIP1; GRIA1; GRIA2; GRID1; DLG3; CDH2; CTNNB1; CASK; GRIK2;
GRIK4; CTNND1; PRKAA1; LIN7B; GRID2; GOLM1 (EBI-736856); GPAA1 (EBI-736877); LRSAM1 (EBI-737066);
MLF1 (EBI-735133)
HUWE1 CDKN2A (EBI-625921); UBL4A (EBI-2515855); FAF2 (EBI-2009967); UBE2E3 (EBI-2339614); GIYD2 (EBI-2372444);
P53 EBI-626140); VCPIP1 (EBI-2513235); USP7 (EBI-2513133); MYC (EBI-1237540); UBXN1 (EBI-2010040); CDC6;
USP49 (EBI-2512828); USP50; SMAD2; CCL1; RNF11; SMAD9; MCL1; ATM
IL1RAPL1 NCS-1/FREQ; DLG4 (Pavlowsky et al. 2010); CFTR (EBI-1171098)
JARID1C/
KDM5C
HIST2H3A; SMAD3; RNF2, MAX, REST NCOR1, HDAC1, HDAC2, E2F6, RING1, CBX3;
KIRREL3 CASK (Bhalla et al. 2008)
MAGT1 None known
MBD5 None known
MECP2 SIN3A; LBR; HDAC1; PRPF40A; SPI1; PRPF40B; SKI; DNMT; CDKL5; RBPJ; YBX1; CBX5; SMARCA2; SMARCB1;
ATRX*; RCOR1; GTF2B; SUV39H3; HIST2H3A; SIN3B; NCOR1; SMARCE1
NLGN4X DLG4; DLGAP2
OPHN1 RHOA; RAC1; CDC42
PAK3 RAC1; RAF1; ARHGEF6; ARHGEF7; SYN1; PXN; MYO6; GIT2; NCK1; CDC42
Table 3 NS-ID Gene Interactions Interactions were determined using
4 databases: BioGRID (www.thebiogrid.org), HPRD (www.hprd.org),
String (www.string-db.org) and IntAct (http://www.ebi.ac.uk/intact).
Interactions from all 4 databases are recorded for each gene. For each
interaction identified on these websites there is a link to the
appropriate publication for that interaction. In BioGRID, the publica-
tion can be found by clicking on the “publication” link. For HPRD the
publication can be found by clicking on the “experiment type” next to
each interaction. For String, clicking on the “experiments” link and
then on the “details” for the interaction brings up the published
abstract. For IntAct, the EBI identification number has been provided
for each protein, and this can be queried on the IntAct database to find
the publication information. Interactants not found in these databases
have been cited independently. *Interactions have been identified in
animal studies
J Neurodevelop Disord (2010) 2:182–209 195junctions (NMJ) and in the CNS, but appears to have
distinct functions at each location (Stephan et al. 2008;
Bezakova and Ruegg 2003). Neurotrypsin-dependent agrin
cleavage appears to be an essential process for the formation
ofdendriticfilopodiainthehippocampus,andisdependenton
LTP generated by NMDA and AMPA receptors (Matsumoto-
Miyai et al. 2009). Dendritic filopodia are the precursors for
new dendritic spines in activity dependant synaptogensis
(Jontes and Smith 2000). With so many NS-ID genes coding
for proteins that are involved in organizing, signaling and
downstream effects of ionotropic glutamate receptors, it is
likely that excitatory synapses are very important in the
normal development of intellectual function. CRBN is
another NS-ID gene that codes for a synaptic protease
(Higgins et al. 2004). Although its function is not as well
characterized as PRSS12, it is known to contain a LON-
Protease domain. It, however, is better known to exist in
neurons and assist in coordinating the expression function of
Ca
2+-dependant K
+ channels (Higgins et al. 2008).
Cell adhesion
Earlier in this review, NLGN4 was discussed as a neuronal
cell adhesion molecule involved in NS-ID etiology. Cell
adhesion molecules are critical for the maintenance of
synaptic structure and neuronal plasticity (Sudhof 2008).
Not surprisingly, several ID genes are involved in cell
adhesion. CDH15 is a cadherin gene localized in the brain
and skeletal muscle (Bhalla et al. 2008). Mutations of this
gene in individuals with ID were found to decrease cell
adhesion by greater than 80% (Bhalla et al. 2008).
PCDH19, a protocadherin, has also been implicated in
epilepsy with mental retardation limited to females (EFMR)
(Dibbens et al. 2008; Hynes et al. 2009). Additionally, it
has been postulated that TSPAN7 is involved in a complex
of ß-integrins, which are involved in cell–cell and cell–
matrix interactions (Zemni et al. 2000).
The RHO pathway
Rho GTPases are also a common pathway in NS-XLMR (see
Tables 2 and 3). OPHN1, PAK3, ARHGEF6 and FGD1 all
encode proteins that are involved in cellular signaling
through Rho GTPases or downstream effects (Ramakers
2002). OPHN1 encodes oligophrenin 1, which has been
found to stimulate the GTPase activity of RhoA, Rac1 and
Cdc42 (Billuart et al. 1998). PAK3, a serine/threonine
protease that plays a role in regulating the actin cytoskeleton,
Table 3 (continued)
Gene Name Interacting proteins (IntAct; STRING; BioGRID; HPRD)
PQBP1 POU3F2; POLR2A; EEF1A1 (EBI-730579) ATXN1; MED31 (EBI-730576); SF3A2; TXNL4A; WBP11 (EBI-956742);
RIF1 (EBI-732938); C14ORF1 (EBI-735456); RAB8A (EBI-737426); C1ORF103
PRSS12 None known
PTCHD1 None known
RPS6KA3 MAPT; MAPK1; MAPK3; PLD1; BAD; HIST3H3; CREB1; FGF2; NR4A1; SYT3; KRT18; CREBBP; MAPK14; PEA15;
IGF1; PDPK1; GSTK1 (EBI-1079890); CSNK2B (EBI-1371784)
SHANK2 DLGAP1-4; DNM2; ARHGEF7; CTTN; SSTR2*; DLG4; DYNLL1; DYNLL2; MYO5A; LPHN1; LPHN2; BAI2;
SLC9A3; BAIAP2; NCK1 (EBI-1968244); PLCG1 (EBI-1971189); PIK3R1 (EBI-1969713); PPP1R14A* (EBI-776423);
SRC (EBI-1960646); GRB2 (EBI-1963670); GRIN2B* (EBI-770442); GRIN1 (EBI-396959); HOMER/Ves1 (Hayashi et
al. 2009); CRK (EBI-1959944)
SHROOM4 MYO6; MYO1A; MYO1C; MYO9B; CORO1A; CD2AP
SLC6A8 CD59
STXBP1 STX1A; STX1B; STX2-4; STX5* SYTL4; STX1B2; SNAP25; ABPA1/Mint1; APBA2*; DLG4*; TUBB2A; TUBA4A;
MAPT; HGS; DOC2A; PLD1; CDK5R1; NEFH; CDK5; USO1; PRKCA; PRKCB1; PRKCG
SYNGAP1 ULK1; DLG4; DLG3; ULK2; CAMK2A; MPDZ; DLG3; DLG4; GRIN2A; GRIN2B; GRIN1; TRIP6; PDGFRB; KDR
SYP GRB2; VAMP2; SIAH1; SIAH2; AP1G1; STX1A; EPOR
TSPAN7 KPTN; FYTTD1
TRAPPC9 TRAPP complex; IKBKB; MAP3K14
TUSC3 PPP1CA
UPF3B UPF1 (EBI-536644); UPF2 (EBI-374193); RBM8A; NCBP1 (EBI-1776148); HBB; USP21 (EBI-2512177); EIF6; EIF4A3
(EBI-464796); UPF3A; TTC19 (EBI-374205); MCRS1 (EBI-374202); EIF4G1 (EBI-464801); ITGB3BP (EBI-732256)
ZNF41 SMAD2
ZNF674 None known
ZNF711 PHF8 (Kleine-Kohlbrecher et al. 2010)
ZNF81 None known
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Fig. 1 a The Nucleus: Many ID genes are involved in transcriptional
regulation. Several of these genes encode transcription factors, such as
the zinc fingers, PQBP1, ARX and FMR2. CC2D1A and TRAPPC9
activate the NF-κB transcription factor. Epigenetic regulation can also
be seen in NS-ID genes. Mutations in genes encoding methyl-binding
proteins like MeCP2, ATRX and MBD5, as well as chromatin
remodeling proteins like JARID1C and BRWD3, result in ID. b The
Glutamate Excitatory Synapse: The pre-synaptic portion of the
excitatory synapse is where synaptic vesicles containing the neuro-
transmitter glutamate are exocytosed. The NS-ID-associated scaffold-
ing protein CASK functions here, as do various other proteins
involved in neurotransmitter release that have been implicated in
NS-ID or autism, such as SNAP25, STXBP1, SYP, GDI1 and
NRXN1. Postsynaptic excitatory synapses contain up to three types
of ionotropic glutamate receptors as well as metabotropic glutamate
receptors. In these receptors and their complex protein interactions, we
find many proteins that are involved in NS-ID. Mutations in genes
coding for subunits of ionotropic glutamate receptors, such as GLuR6
(Kainate receptor subunit) and GRIA3 (AMPAR subunit), cause MR.
Additionally, many proteins in the postsynaptic density (PSD)
including scaffolding and adhesion proteins (SAP102, SHANK3,
NLGN4) have also been implied in the genetics of NS-ID and autism.
CRBN is involved in regulating the expression of Ca
2+ dependant K
+
channels (BKCa, encoded by KCNMA1), and resulting ionic currents,
at the synapse. IL1RAPL1, a relatively common genetic cause of NS-
MR and autism is present in the PSD, as are OPHN1 and SYNGAP,
which is a cause of autosomal dominant NS-ID. SYNGAP activates
RAS, which leads to several signal transduction pathways resulting in
transcriptional activation, including the ERK/MAP and RHO path-
ways, each of which have downstream effectors that are coded for
other NS-ID related genes (Rho: PAK3, OPHN1, ARHGEF6, FGD1,
DOCK8; ERK/MAPK: RPS6KA3, PAK3). A number of other autism
or ID-associated proteins are also believed to function at the synapse
(DPP6, DPP10, PCDH9, SLC6A8, PRSS12), but are not shown in this
representation (Molinari et al. 2002; Hahn et al. 2002; Marshall et al.
2008; Hynes et al. 2009)
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al. 1995; Daniels and Bokoch 1999). ARHGEF6 encodes a
guanine nucleotide exchange factor (GEF) for Rac1 and
Cdc42 that interacts with PAK family proteins (Manser et al.
1995; Daniels and Bokoch 1999). FGD1 is also a GEF for
Cdc42 (Zheng et al. 1996). All of these gene products
interact in the Rho signaling pathway, suggesting that events
triggered by this pathway, such as vesicular trafficking in
dendritic spines and cytoskeleton organization, may be
important processes in cognition and that, when disturbed,
cause ID.
Synaptic vesicle trafficking and exocytosis
Several NS-ID genes are involved in neurotransmitter
release by exocytosis (see Fig. 1). This process has been
extensively studied over the years and has a number of key
components. The SNARE complex is essential for neuro-
transmitter release. Reconstitution experiments have shown
that SNARE alone is sufficient for membrane fusion
(Weber et al. 1998). SNAP25 (MIM: 600322), a subunit
of plasma membrane SNARE complexes (t-SNARE) has
been associated with ID through SNP analysis (Gosso et al.
2008). Studies of common variants in SNAP25 have shown
significant association with the extremes of IQ (Gosso et al.
2008). This is one of the few examples of common variants
playing a role in intellectual disability.
STXBP1 (Munc18-1) (MIM: 602926) binds to syntaxin-
1, the other subunit of the t-SNARE complex, and there is
evidence that it has a variety of functions in exocytosis
including vesicle priming, SNARE assembly, localization
of syntaxin-1 in the plasma membrane, as well as
regulatory effects (As reviewed by Rizo and Rosenmund
2008). Truncating mutations in STXBP1 have been reported
in two cases of NS-ID, and in ID with non-syndromic
epilepsy (Hamdan et al. 2009a, b).
Additionally, SYP, which encodes synaptophysin, an
integral membrane protein found in transport vesicles in
the brain, also causes NS-ID (Tarpey et al. 2009). It
interacts with synaptobrevin (VAMP2) and is involved in
the regulation, sorting and distribution of synaptobrevin in
neurons, but the molecular mechanism by which this occurs
is unknown (Bonanomi et al. 2007). Synaptobrevin is the
essential component of the vesicle SNARE complex (v-
SNARE) (Rizo and Rosenmund 2008). Four mutations
have been found in SYP in individuals with NS-ID and ID
with epilepsy (Tarpey et al. 2009).
The Rab3 family of small GTPases is also known to be
important in membrane trafficking and the release of
neurotransmitters. GDI1 encodes a GDP-dissociation in-
hibitor, which causes GTPases Rab3a and Rab3b to remain
inactive by maintaining it in their GDP-bound form
(D’adamo et al. 1998; Bienvenu et al. 1998). Rab3 GTPase
isoforms A, B and C are localized to synaptic vesicles, and
function to regulate neurotransmitter release by regulating
the SNARE complex (Fischer von Mollard et al. 1994;
Geppert et al. 1997; Gonzalez and Scheller 1999).
Interestingly, the scaffolding protein CASK interacts with
rabphilin3a, an upstream effector of Rab3a (Zhang et al.
2001). Rabphilin3a maintains Rab3a in its active, GTP-
bound state, so disruptions in the rabphilin3a complex with
CASK may have a deleterious impact on its interaction with
Rab3a (Geppert et al. 1997). It is possible that this leads to
the disruption of synaptic vesicle exocytosis, but requires
further investigation. Another Rab family gene, Rab39, was
found to be mutated in two families with ID and variable
other phenotypes including autistic features, macrocephaly
and epilepsy (Giannandrea et al. 2010). This suggests that
Rab family proteins are important for normal cognitive
development and other Rab genes may be considered as
candidates for ID.
The ERK/MAPK pathway
The ERK/MAPK pathway is a signaling cascade that
responds to growth factors. This pathway is particularly
interesting because it is required for certain types of
synaptic plasticity (Zhu et al. 2002; Thomas and Huganir
2004). Genes coding for ERK/MAPK pathway proteins and
regulators have also been found to cause NS-ID. SynGAP,
discussed earlier in this review, has been shown to
negatively regulate the ERK/MAPK pathway. When Syn-
GAP activity was depleted by RNAi, ERK activation by
NMDAR became sustained (Kim et al. 2005). Conversely,
over-expression of SynGAP in cultured neurons diminishes
ERK activation (Rumbaugh et al. 2006). These results
suggest that SynGAP is necessary for terminating ERK
activation thus negatively regulates excitatory synaptic
transmission and AMPAR cell surface expression (Kim et
al. 2005; Rumbaugh et al. 2006). RPS6KA3 is another
NS-ID gene that is involved in ERK/MAPK signaling
(Merienne et al. 1999). RPS6KA3 encodes Ribosomal S6
Kinase (RSK) 2, which is a downstream effector of the
ERK signaling pathway. ERK activation of RSK2 causes
phosphorylation of SHANK3, and appears to be required
for normal functioning of AMPARs (Thomas and Huganir
2004). These findings suggest that the ERK/MAPK
pathway is an important pathway for normal cognitive
development.
Zinc finger proteins
A number of zinc finger proteins, autosomal and X-linked,
have been implicated in NS-ID. Both missense and
nonsense mutations cause NS-ID in these genes. ZNF41,
ZNF81 and ZNF674 are members of a cluster of 7 highly
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and are thought to be involved in transcriptional regulation
(Lugtenberg et al. 2006). These zinc finger proteins are all
part of the Kruppel-associated box (KRAB) family, which
is the largest class of zinc finger proteins (Urrutia 2003).
KRAB family zinc finger genes tend to occur in clusters in
the genome. The largest such cluster is present on 19q13
(Rousseau-Merck et al. 2002), and contains more than half
of the known KRAB domain zinc finger proteins. KRAB
family zinc finger proteins have been shown to contribute
to transcriptional repression by binding to co-repressors
(Witzgall et al. 1994; Margolin et al. 1994) They have been
found to function in the formation of hp-1 heterochromatin
via complex formation with Kap-1 and SetDB1, a histone 3
lysine 9 (H3-K9) methylase (Schultz et al. 2002). During
mouse embryogenesis, KRAB domain proteins also cause
irreversible gene silencing through methylation of promoter
sequences (Wiznerowicz et al. 2007). It is also notable that
KRAB family zinc finger proteins are only present in
higher vertebrates such as mammals, birds and amphibians,
but not in fish or lower eukaryotes, and it has been
postulated that they may have evolved to play an important
role in functions such as the nervous or immune systems
(Urrutia 2003).
The gene ZNF711 is also implicated in NS-ID and is
located on the X-chromosome (Tarpey et al. 2009).
Currently the function is unknown but its sequence and
domain structure bears similarity to other zinc fingers
involved in transcriptional activation (Tarpey et al. 2009).
ZC3H14, another zinc finger gene putatively involved in
NS-ID (Garshasbi et al. 2009 Abstract), contains a poly-
adenosine RNA binding domain, and co-localizes with the
splicing factor SC35, suggesting a potential role for it in
mRNA processing, but further investigation is required to
support this claim (Leung et al. 2009).
Since these genes are involved in NS-ID, it is possible
that their protein products target the regulation of specific
neuronal genes that are involved in cognitive development,
learning or memory formation, resulting in an NS-ID
phenotype. Future studies that detail the genes or chromo-
somal regions that are influenced by zinc finger proteins
will result in a clearer picture of the mechanism by which
mutations in zinc finger proteins cause NS-ID. Numerous
other NS-ID genes also appear to be involved in transcrip-
tional regulation (Gecz et al. 2009).
Transcriptional regulation and chromatin remodeling
In addition to the zinc finger proteins, several other
transcriptional regulators are implicated in NS-ID. Regula-
tion of transcription appears to be a common theme among
NS-ID genes. CC2D1A, an autosomal gene, is responsible
for repression of transcription of several serotonin and
dopamine receptor genes, and is a putative activator of the
NF-κB transcription factor (Basel-Vanagaite et al. 2006).
Likewise, TRAPPC9 is an activator of the NF-κB pathway
(Hu et al. 2005). NF-κB up-regulates the expression of
many neuronal genes, as well as genes of the immune
system. Multiple studies have implicated NF-κB in long-
term memory formation (Albensi and Mattson 2000;
Kassed et al. 2002; Meffert et al. 2003). Additionally,
evidence suggests that NF-κB is induced in the hippocam-
pus by group I metabotropic glutamate receptors (GpI-
mGLuRs; O’Riordan et al. 2006).
ARX is a homeobox-containing gene that is part of the
Aristaless-related gene family. This is a family of transcrip-
tion factors that are required for various essential events
during vertebrate embryogenesis, including CNS develop-
ment (Meijlink et al. 1999). Based on the experimental data
and gene structure it has been speculated that ARX regulates
transcription by both gene activation and suppression (as
reviewed by Friocourt et al. 2006). Many mutations have
been identified in ARX causing intellectual disability.
Diseases caused by mutations in this gene include: West
syndrome (Stromme et al. 2002a), Partington syndrome
(Stromme et al. 2002b), XLAG (Kitamura et al. 2002),
XLMR (Bienvenu et al. 2002), Proud Syndrome (Kato et
al. 2004), and various forms of epilepsy (Stromme et al.
2002a, b; Scheffer et al. 2002). There seems to be a
genotype/phenotype correlation between the location and
nature of the mutation and the severity of the phenotype.
Loss of function mutations such as truncations and
mutations occurring in the highly conserved homeobox
domain tend to result in more severe disease including brain
malformations as is seen in Proud Syndrome and XLAG
(Sherr 2003; Gecz et al. 2006). This gene is one of the most
frequently mutated in XLMR. Strikingly, one mutation, a
24-bp in frame duplication that expands the 12-polyalanine
tract to 20, is found in >5% of individuals with XLMR
(Bienvenu et al. 2002; Stromme et al. 2002a, b; Friocourt et
al. 2006). This mutation is also found in individuals with
other ARX related S-ID, emphasizing the pleiotropy
observed with ARX mutations (Gecz et al. 2006; Friocourt
et al. 2006). The activity of this transcription factor is
clearly essential for normal cognitive development, and
further study of the genes regulated by ARX will be
important for our understanding of NS-ID.
Epigenetic regulation is also an important mechanism by
which transcription is regulated. MECP2 and ATRX, two
genes that function in epigenetic regulation, have been
linked to NS-ID etiology. MECP2 encodes the methyl CpG
binding protein 2 (MeCP2), which is believed to act as a
transcriptional modulator, capable of repressing or activat-
ing genes through long-range chromatin re-organization
through binding to methylated CpG DNA (see Gonzales
and LaSalle 2010 for review). MeCP2 also interacts with
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neurons is disturbed (Nan et al. 2007). Mutations in ATRX
cause changes to DNA methylation at several specific
highly repeated sequences during development, and MeCP2
mutations cause a loss of transcriptional regulation through
binding methylated CpG-containing DNA (Dragich et al.
2000; Gibbons et al. 2000). Interestingly, these are both
genes in which mutations cause variable phenotypes.
MECP2 mutations cause Rett syndrome, MRXS13, LUBS
X-linked ID syndrome, autism and NS-ID, and ATRX
mutations cause alpha-thalassemia/MR syndrome, MR-
hypotonic facies syndrome, alpha-thalassemia myelodys-
plasia syndrome and NS-ID.
Chromatin remodeling, a mechanism that is essential for
both gene expression and the maintenance of chromatin
structure, also appears to play a role in NS-ID etiology.
JARIDIC, also known as KMD5C, is one of the more
common genes related to X-linked intellectual disability
with over twenty mutations known in XLMR patients
(Tzschach et al. 2006; Tahiliani et al. 2007). It is a histone
demethylase containing a PHD-finger domain that is
characteristic of zinc finger proteins and specifically
demethylates di- and tri-methylated histone 3 lysine 4
residues (H3K4me2/me3) (Cloos et al. 2008; Iwase et al.
2007; Tahiliani et al. 2007; Christensen et al. 2007).
Trimethylation at this residue is extremely important for
transcriptional regulation and chromatin structure. It is
likely involved in REST-mediated transcriptional repres-
sion. It has been shown to regulate the expression of several
REST-mediated genes, as well as regulate the H3K4me2/
H3K4me3 levels at their promoters (Tahiliani et al. 2007).
JARID1C has many allelic variants causing disease and has
been linked with NS-ID, S-ID and autism (Jensen et al.
2005; Abidi et al. 2008; Adegbola et al. 2008).
Two other PHD-domain genes are mutated in different
forms of ID. Mutations in PHF6 (MIM: 300414) on
Xq26.3 result in Borjeson-Forssman-Lehmann syndrome
(BFLS). This is a form of S-ID presenting with severe ID,
epilepsy, obesity, endocrine defects and several dysmorphic
features (Brun et al. 1974). Mutations in PHF8 (MIM:
300560) on Xp11.2 cause ID with characteristic facial
features and cleft lip/palette—a form of S-ID also known
as Siderius X-linked mental retardation syndrome. The
gene functions as an H3K9me1/me2 demethylase and
contains a PHD finger that binds to H3K9me2/me3
(Kleine-Kohlbrecher et al. 2010). It has recently been shown
that PHF8 interacts with ZNF711, and that these two protein
products co-localize at PHF8 target genes in the nucleus,
resulting in transcriptional activation (Kleine-Kohlbrecher et
al. 2010). Interestingly, JARID1C is one of these target genes
(Kleine-Kohlbrecher et al. 2010). This study shows that
PHF8, ZNF711,a n dJARID1C are involved in a common
pathway of transcriptional regulation and chromatin
remodeling, providing further evidence that these functions
are important for normal cognitive development. It also
illustrates the value of identifying pathways involved in
transcriptional regulation, for the study of ID.
MBD5 (methyl binding domain 5) has been proposed as
an autosomal dominant candidate for ID. Mutations in this
gene result in variable phenotypes, ranging from syndromic
to apparently non-syndromic ID (Wagenstaller et al. 2007).
Although not much is known about the function of this
gene in humans, it is a methyl-CpG binding protein and
may, like other methyl-binding proteins, function in
regulation of transcription. It is also notable that BRWD3,
a gene found in both NS-ID and S-ID contains a
bromodomain—a conserved protein motif that recognizes
acetylated lysine residues, and is found in chromatin
associated proteins and histone acetyltransferases (Field et
al. 2007; Sanchez and Zhou 2009). Although there is
currently no experimental data to confirm that BRWD3 is a
chromatin modifying protein, it is a possibility based on its
motif structure (Field et al. 2007). Further work on both of
these gene products will provide evidence of whether or not
they are important for chromatin remodeling and regulation
of transcription.
Because of the variable phenotypes resulting from
mutations in this class of genes, it seems likely that
chromatin maintenance and remodeling play a crucial role
in normal cognitive development. It is possible that
different mutations might lead to varying levels of protein
function, and that function might be retained or disturbed
differentially by different mutations. In all of these genes,
multiple allelic variants are involved and several forms of
S-ID as well as NS-ID may result from mutation.
These are only some examples of potential mechanisms
by which NS-ID is developed. As we learn more about
genes involved in NS-ID, more common biological path-
ways will become apparent, and will lead us to an
understanding of how it is acquired, and what can be done
to prevent it or alleviate it in genetic cases.
Connecting ID and autism
CNVs, or structural variation within the genome, appear to
contribute significantly to the etiology of both ID and
autism. It is often necessary to look at these diagnoses
together, as there is significant overlap between them. ID is
presentin~67%ofindividualswithautism(Fombonne2003).
Additionally, in a study performed on an ID population, 28%
met the criteria for an autism diagnosis on the ADI-R scale
and only half of these had been previously diagnosed
(Bryson et al. 2008). Similar studies have been replicated
in the past, showing that within ID populations, the
prevalence of autism is 8–20%, and that many more
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Disorder (ASD; Bryson et al. 2008; de Bildt et al. 2005;
Stromme and Diseth 2000; Nordin and Gillberg 1996;D e b
and Prasad 1994; Wing and Gould 1979).
ID and autism have multiple overlapping phenotypic
domains. The three major phenotypes that characterize
autism—language abnormalities, social deficits and stereo-
typies—can often be seen to varying degrees in ID
individuals. Individuals with ID often display stereotypies,
which tend to become more pronounced and often self-
injurious, as IQ decreases (Symons et al. 2005). Studies
have found that 30–60% of individuals with ID display
some form of stereotypy (Bodfish et al. 1995; Bodfish et al.
2000; Goldman et al. 2009). Language deficits are often
particularly severe in individuals with severe and profound
ID.
Many ID syndromes have an incidence of autism
that is significantly higher than the incidence for the
general population. For example, A current review of the
literature shows that 25–47% of individuals with fragile X
syndrome, 5–10% of individuals with Downs syndrome,
and 16–48% of individuals with tuberous sclerosis (TSC)
have a concomitant autism/PDD diagnosis, compared to
0.3–0.6% in the general population (Fombonne 2003,
Molloy et al. 2009). Other ID syndromes that have high
incidences of concordant autism include Angelman
syndrome, Rett syndrome, Joubert Syndrome and Cohen
syndrome.
Although autism and ID constitute two separate diagno-
ses, the overlap cannot be ignored. These overlaps are
difficult to quantify genetically due to the heterogeneity of
both conditions, and the apparent contribution of rare
genetic variants to both diseases. However, there are several
genes that appear to be causative for both conditions. The
Neuroligin 4 (NLGN4) gene has been linked to autism by
several studies (Laumonnier et al. 2004; Marshall et al.
2008; Jamain et al. 2003). However, in 2004, Laumonnier
et al. identified a family containing individuals with NS-ID,
with or without ASD, segregating with a NLGN4 mutation
(2004). More recently, a truncating mutation was found in
SHANK3 in an individual with NS-ID (Michaud et al. 2009
Abstract). SHANK3 has also been found to cause autism in
several studies (Durand et al. 2007; Marshall et al. 2008).
PTCHD1 is another X-linked gene that has been
implicated in autism and NS-ID. A CNV, which deletes
that copy of PTCHD1 entirely, causes NS-ID in one family
(Noor et al., in press). Another CNV, which results in a loss
of the first exon and upstream region of PTCHD1, results in
autism in another family (Noor et al., in press). IL1RAPL1,
which was initially identified as a cause of NS-ID, and has
been shown to cause NS-ID in several individuals, has also
been implicated in autism (Carrie et al. 1999; Marshall et al.
2008; Piton et al. 2008; Bhat et al. 2008). Similarly, a
missense mutation in the NS-ID gene JARID1C was found
in an autistic individual (Adegbola et al. 2008). Most
recently, a de novo CNV deletion overlapping SYNGAP1
was identified in a female autism proband (Pinto et al.
2010). These genetic links are of much interest, particularly
due to the strong phenotypic overlap seen in NS-ID and
autism. These common genes will be an important factor in
teasing out which biochemical processes are disturbed in
different forms of developmental delay, and why a particular
mutation in an individual might lead to one condition rather
than the other.
It is also interesting to note that polymorphisms in
GRIK2, one of the NS-ARID genes, have been associated
with autism in several studies (Jamain et al. 2002; Shuang
et al. 2004; Kim et al. 2007). One study found GRIK2 to be
in linkage disequilibrium in an autistic population (Jamain
et al. 2002). They found a SNP that causes an amino acid
change and shows enhanced maternal transmission to be
present in 8% of their autistic population, but in only 4% of
the control population (Jamain et al. 2002). They propose
that GRIK2 polymorphisms may be associated with an
increased susceptibility to autism. Two additional indepen-
dent studies from different populations have shown similar
results (Shuang et al. 2004; Kim et al. 2007). However, the
studies of GRIK2 in autism indicate a dominant model of
inheritance, whereas inheritance of GRIK2 in NS-ID is
recessive. It is unlikely that the GRIK2 polymorphisms alone
cause autism, but they may contribute to the overall ASD
susceptibility. As nonsense mutations in GRIK2 are respon-
sible for the ARID, perhaps missense changes contribute to
other neuropsychiatric disorders such as autism.
Potential therapies
For some NS-ID cases caused by single gene mutations,
there is the potential for treatment using various categories
of gene therapies. Some of these gene therapies are currently
under investigation in animal models and humans and have
shown promising results for ID-related phenotypes in mouse
models.
Transgenic mouse models have been used to assess the
effects of re-introducing functional MECP2 (the gene that
causes Rett syndrome and some cases of NS-ID) into
MECP2 deficient mice with some success. MECP2 null
mice have been generated with transgenes that can be
conditionally induced to express MECP2. Therefore, the
gene may be expressed at experimental time points, which
allows for an assessment of pharmacological relevance of
re-introducing endogenous MECP2 or introducing ectopic
MECP2 (Luikenhuis et al. 2004;G i a c o m e t t ie ta l .2007;
Guy et al. 2007; Jugloff et al. 2008). Certain neurological
and behavioral phenotypes of these mice were rescued
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damage done by lack of MECP2 is not completely
irreversible, and that ID phenotypes can be rescued to
some extent (Luikenhuis et al. 2004; Giacometti et al.
2007; Guy et al. 2007; Jugloff et al. 2008). Mice lacking
MECP2 have a Rett-like phenotype, although presum-
ably, similar phenotype rescue methods could be used to
target NS-ID genes. One of the main issues with applying
this strategy in humans is the problem of how to deliver
functional copies of the gene to relevant tissues and cells
without causing over-expression, which itself may have
adverse effects.
A method that has been applied to the treatment of
neuromuscular disorders, and may be of potential use for
NS-ID, is exon skipping using antisense oligonucleotides
(AO) or siRNA (Arnett et al. 2009). This therapy allows the
exon containing the truncating mutation to be skipped so
that the rest of the gene is transcribed (Arnett et al. 2009).
The AOs are delivered using viral vectors. Major issues
with this method include immunogenicity to the foreign
virus and DNA (Arnett et al. 2009). Additionally, this
method has only been assessed for effectiveness in muscle
tissues. One of the main issues here would be to identify a
vector that could transverse the blood-brain barrier. How-
ever, if this could be overcome, it could be an effective way
to overcome nonsense-mediated RNA decay of ID genes,
and as a consequence restore some function to NS-ID
proteins.
Another attractive therapy, and perhaps the one with the
most empirical support in humans is aminoglycoside-
mediated suppression of nonsense mutations. Aminoglyco-
sides, more generally known for their antibiotic proper-
ties, can cause read-through of nonsense mutations, so
that translation would not be arrested by the mutation,
and potentially full length protein may be produced. The
use of aminoglycosides has been proposed and has been
relatively successful for the read-through of several
disease causing genotypes, including those found in
MECP2 that cause Rett syndrome (Brendel et al. 2009).
In HeLa cells transfected with common Rett syndrome
disease variants of the MECP2 gene, read-through after
treatment with aminoglycosides was between 10% and
21% depending on the variant (Brendel et al. 2009).
Similar results have been achieved for other disease-
causing genes. In studies of cystic fibrosis (CF) in
humans, individuals with nonsense mutations in the CFTR
gene had aminoglycoside (gentamicin) drops administered
to their nasal pathway and showed some restored
function of CFTR in 90% of patients (Wilschanski
et al. 2003).
Although this method has had relatively encouraging
results, there are some issues with it. There is evidence to
suggest that naturally occurring stop codons lead to
efficient termination due to their context, whereas prema-
ture stop codons may be more susceptible to read-through
due to their location (Kerem 2004). This notion is further
supported by the fact that certain mutations respond more
efficiently to aminoglycosides than others (Kerem 2004).
However, it is still possible that issues may arise with
pseudogenes or other genes with nonsense mutations that
have not resulted in a phenotype. There is potential for
“junk” DNA to be transcribed and then compete for active
sites with normal, functional proteins. Additionally, evi-
dence has been found in CFTR nonsense mutation cell lines
that the level of nonsense-mediated decay (NMD) has an
effect on the efficiency of aminogylcosides (Linde et al.
2007). This makes sense, as NMD would result in there
being less available transcript to read through. Other
potential issues include nephrotoxicity and ototoxicity that
occurs with aminoglycoside usage (Nagai and Takano
2004). However, this therapy should not be ruled out for
potential usage in some monogenic NS-ID cases.
Overall, the fact that, for some therapies, there is a
demonstrable improvement in the condition of mice with
features of ID suggests that damage to the nervous system
may be reversible in some types of ID. This has provided
significant hope for potential treatment of ID and improv-
ing functional behaviors in individuals with ID. While this
is very encouraging, more information is required
concerning the genes and biological pathways involved in
ID, in order to progress towards the goal of medicinal
treatment of human ID.
Discussion
As more genes are being identified that cause NS-ID,
certain pathways are emerging as central contributors to
normal cognition, and researchers are beginning to fit
pieces of the puzzle together. The hope is that this will
result in greater accuracy in the selection of new candidate
disease genes, as well as an enhanced efficiency for genetic
diagnostics for NS-ID. This will also be essential to the
next stages in the study of intellectual disabilities, as we
move from identifying monogenic causes of NS-ID towards
identifying more complicated genetic mechanisms, as well
as identifying all the molecular complexes and pathways
(and the ways in which they interact with each other) that
are involved in human neurological development and
cognitive functioning. For example, genes involved in
neurotransmitter trafficking and release are very good
candidates, as are genes that encode regulators of excitatory
synapses. Based on the analysis of functions of genes
involved in NS-ID, it is apparent that excitatory synapses
play an integral role in the basis of cognition. Additional
evidence of this is that memory and learning have been
202 J Neurodevelop Disord (2010) 2:182–209linked to LTP and LTD at these synapses, and thus both
organization and communication at these locations are
likely to affect cognition.
Additionally, transcription regulators such as zinc finger
proteins and chromatin modifiers play a significant role in
NS-ID etiology, although many of these genes cause
variable NS-ID phenotypes. The location and nature of
mutations within these genes may contribute to the
phenotypic manifestation of syndromic versus non-
syndromic ID. Learning more about the classes and
functions of genes activated by these transcription regu-
lators would improve our understanding of how mutations
in these NS-ID genes exert an effect at the molecular level,
as well as the phenotypic consequences. The same is also
true for the signaling pathways, such as Rho and ERK/
MAPK, implicated in NS-ID, where research into the
downstream effects of mutations in these genes will assist
our knowledge of the role of these pathways in normal
neurodevelopment and cognition.
Interestingly, a recent study was conducted that analyzed
SNP association across functional protein groups and
found that genetic variations in synaptic heterotrimeric G-
proteins are associated with cognitive function (Ruano et
al. 2010). Although none of these genes had been
implicated in intellectual disabilities previously, the ap-
proach suggests that, in addition to the biological path-
ways, specific classes of genes may also be fundamental
for cognitive development.
The genetic causes of NS-ID are rapidly being uncovered
and will be essential for genetic counseling, diagnostics and
treatments in the future. The knowledge of genes that cause
NS-ID will have an impact on how cases are treated in a
clinical setting. Microarrays for mutation screening of
known disease genes, as well as exome and whole genome
sequencing, will likely become essential tools both for
clinical diagnostic purposes and research. As microarray
and next generation sequencing technology becomes less
expensive and more accessible, identification of new genes
for NS-ID will accelerate rapidly. This will inevitably
feedback into clinical diagnostics and genetic counseling,
with the addition of many more genes to the current
catalogue of NS-ID genes. This, in turn, will further aid our
understanding of the molecular pathways and processes
involved in neurodevelopment and cognition.
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